ES2377012T3 - Método para identificar un sujeto susceptible de desarrollar insuficiencia cardíaca determinando el nivel de galectina-3 o trombospondina-2 - Google Patents

Método para identificar un sujeto susceptible de desarrollar insuficiencia cardíaca determinando el nivel de galectina-3 o trombospondina-2 Download PDF

Info

Publication number
ES2377012T3
ES2377012T3 ES04765681T ES04765681T ES2377012T3 ES 2377012 T3 ES2377012 T3 ES 2377012T3 ES 04765681 T ES04765681 T ES 04765681T ES 04765681 T ES04765681 T ES 04765681T ES 2377012 T3 ES2377012 T3 ES 2377012T3
Authority
ES
Spain
Prior art keywords
galectin
rats
heart failure
level
cardiac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04765681T
Other languages
English (en)
Spanish (es)
Inventor
Yigal M. Pinto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Maastricht
Original Assignee
Universiteit Maastricht
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Maastricht filed Critical Universiteit Maastricht
Application granted granted Critical
Publication of ES2377012T3 publication Critical patent/ES2377012T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4728—Details alpha-Glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/321—Arterial hypertension
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
ES04765681T 2003-10-09 2004-09-27 Método para identificar un sujeto susceptible de desarrollar insuficiencia cardíaca determinando el nivel de galectina-3 o trombospondina-2 Expired - Lifetime ES2377012T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03078161A EP1522857A1 (en) 2003-10-09 2003-10-09 Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
EP03078161 2003-10-09
PCT/EP2004/010879 WO2005040817A1 (en) 2003-10-09 2004-09-27 Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2

Publications (1)

Publication Number Publication Date
ES2377012T3 true ES2377012T3 (es) 2012-03-21

Family

ID=34306912

Family Applications (2)

Application Number Title Priority Date Filing Date
ES04765681T Expired - Lifetime ES2377012T3 (es) 2003-10-09 2004-09-27 Método para identificar un sujeto susceptible de desarrollar insuficiencia cardíaca determinando el nivel de galectina-3 o trombospondina-2
ES10186331T Expired - Lifetime ES2530567T3 (es) 2003-10-09 2004-09-27 Método para identificar un sujeto susceptible de desarrollar insuficiencia cardíaca determinando el nivel de galectina-3 o trombospondina-2

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES10186331T Expired - Lifetime ES2530567T3 (es) 2003-10-09 2004-09-27 Método para identificar un sujeto susceptible de desarrollar insuficiencia cardíaca determinando el nivel de galectina-3 o trombospondina-2

Country Status (14)

Country Link
US (5) US7888137B2 (enExample)
EP (4) EP1522857A1 (enExample)
JP (5) JP4840744B2 (enExample)
CN (2) CN102998458B (enExample)
AT (1) ATE532073T1 (enExample)
AU (2) AU2004284496C1 (enExample)
CA (2) CA2542033C (enExample)
CY (2) CY1112359T1 (enExample)
DK (2) DK1682907T3 (enExample)
ES (2) ES2377012T3 (enExample)
PL (2) PL2317324T3 (enExample)
PT (2) PT1682907E (enExample)
SI (2) SI1682907T1 (enExample)
WO (1) WO2005040817A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1522857A1 (en) * 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
EP2067042A2 (en) * 2006-09-25 2009-06-10 Universiteit Maastricht Means and methods for diagnosing and/or treating a subject at risk of developing heart failure
EP2109688A4 (en) * 2007-01-23 2010-02-17 Univ Virginia GALECTIN-3 BINDING PROTEIN AS BIOMARKER FOR HEART CIRCULATION DISEASES
WO2009039078A1 (en) * 2007-09-17 2009-03-26 Bg Medicine, Inc. Assessing congestive heart risk in patients treated or potentially to be treated with a peroxisome-proliferator-activator-receptor-gamma agonist or a thiazolidinedione
CA2742265C (en) * 2008-10-29 2014-07-15 Bg Medicine, Inc. Galectin-3 immunoassay
KR20120104167A (ko) * 2009-08-25 2012-09-20 비쥐 메디신, 인코포레이티드 갈렉틴―3 및 심장 재동기화 요법
WO2012003475A1 (en) 2010-07-02 2012-01-05 Bg Medicine, Inc. Statin therapy monitored by galectin- 3 measurement
JP5787895B2 (ja) * 2010-10-18 2015-09-30 原　英彰 筋萎縮性側索硬化症マーカー及びその利用
EP2460890A1 (en) * 2010-12-01 2012-06-06 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Gpnmb/Osteoactivin as a drug target and biomarker in cardiac diseases
JP2014505256A (ja) * 2011-01-31 2014-02-27 ビージー メディシン， インコーポレイテッド 急性冠動脈症候群後の心不全を検出し、予後を判定するためのガレクチン−３の使用
CN103718046B (zh) 2011-03-17 2016-10-12 重症监护诊断股份有限公司 预测不良临床结果的风险的方法
AR086543A1 (es) 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
EP2788761B1 (en) * 2011-12-08 2018-02-28 Eliaz Therapeutics, Inc. Reduction of galectin-3 levels by plasmapheresis
WO2014052803A2 (en) * 2012-09-27 2014-04-03 Siemens Healthcare Diagnostics Inc. Cystatin c and galectin-3 as biomarkers for pulmonary arterial hypertension
JP6366598B2 (ja) * 2012-11-15 2018-08-01 タフツ ユニバーシティー ガレクチンタンパク質阻害剤を用いて被験体の眼の血管新生または繊維症を処置し、調節し、または、予防する方法、組成物、およびキット
CA2973653A1 (en) 2015-01-18 2016-07-21 Diasorin S.P.A. Use of 1,25-dihydroxyvitamin d values in ratio with pth as a prognostic biomarker
CN107614168B (zh) * 2015-05-28 2019-10-25 京瓷株式会社 切削工具
CN112553335A (zh) * 2020-12-17 2021-03-26 核工业总医院 肾细胞癌生物标志物及其应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4632901A (en) 1984-05-11 1986-12-30 Hybritech Incorporated Method and apparatus for immunoassays
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US20010051350A1 (en) 1995-05-02 2001-12-13 Albert Nazareth Diagnostic detection device and method
BE1010935A7 (nl) * 1997-02-19 1999-03-02 Delanghe Joris Richard Siegfri Fenotypering van humaan haptoglobine in serum of plasma door middel van quantitatieve agglutinatie met streptococcus antigenen.
CA2293718A1 (en) 1997-06-10 1998-12-17 Medlyte Diagnostics, Inc. Methods for early detection of heart disease
US20060166276A1 (en) * 1997-09-05 2006-07-27 Lung Health Diagnostics Pty Ltd Method of diagnosis and agents useful for same
DE69841804D1 (de) * 1997-09-05 2010-09-16 Southern Medical Diagnostics P Diagnoseverfahren
ES2244052T5 (es) * 1997-10-24 2011-03-28 SHIONOGI & CO., LTD. Procedimiento de inhibición de la descomposición de péptidos natriuréticos y procedimento mejorado de dosificado de péptidos natriuréticos con la ayuda de los indicados péptidos.
ES2314786T3 (es) * 1998-04-02 2009-03-16 Genentech, Inc. Uso de interferon gamma para el tratamiento de la hipertrofia cardiaca.
CN1327228C (zh) * 1999-01-29 2007-07-18 罗赫诊断器材股份有限公司 鉴定样品中的n－末端前bnp的方法
WO2001006262A1 (en) * 1999-02-19 2001-01-25 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration
WO2001014581A2 (en) * 1999-08-20 2001-03-01 Board Of Regents, The University Of Texas System Hdac4 and hdac5 in the regulation of cardiac gene expression
GB2373500B (en) 2000-02-04 2004-12-15 Aeomica Inc Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
EP1358347A2 (en) 2000-04-05 2003-11-05 Incyte Genomics, Inc. Genes expressed in foam cell differentiation
KR100395254B1 (ko) 2000-10-30 2003-08-21 (주)자리타 바이오텍 종양 발생 예측 키트
AU2002220266A1 (en) * 2000-11-09 2002-05-21 Millennium Pharmaceuticals, Inc. Methods for the identification and the treatment of cardiovascular disease
WO2002038794A2 (en) * 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
ATE506075T1 (de) * 2000-12-08 2011-05-15 Curagen Corp Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
JP4035562B2 (ja) * 2001-01-31 2008-01-23 国立大学法人富山大学 ガレクチン−３誘導能を利用した物質のスクリーニング方法、肝の状態の診断方法およびこれらの方法を利用したキット
WO2002074911A2 (en) 2001-03-19 2002-09-26 Wisconsin Alumni Research Foundation Identification of gene expression alterations underlying the aging process in mammals
US20060019235A1 (en) 2001-07-02 2006-01-26 The Board Of Trustees Of The Leland Stanford Junior University Molecular and functional profiling using a cellular microarray
US7447594B2 (en) 2001-07-10 2008-11-04 Ocimum Biosolutions, Inc. Molecular cardiotoxicology modeling
US20030099958A1 (en) * 2001-09-05 2003-05-29 Vitivity, Inc. Diagnosis and treatment of vascular disease
GB0124145D0 (en) 2001-10-08 2001-11-28 Bayer Ag Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
US20060141493A1 (en) 2001-11-09 2006-06-29 Duke University Office Of Science And Technology Atherosclerotic phenotype determinative genes and methods for using the same
DE60323091D1 (de) * 2002-05-13 2008-10-02 Arexis Ab Autoimmunerkrankungen und nadph-oxidase-defekte
AU2003290537A1 (en) 2002-10-24 2004-05-13 Duke University Binary prediction tree modeling with many predictors and its uses in clinical and genomic applications
JP2006514554A (ja) 2002-11-21 2006-05-11 ワイス 腎細胞癌および他の固形腫瘍の診断法
EP1431399A1 (en) * 2002-12-20 2004-06-23 Clinigenetics Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions
US6889083B2 (en) 2003-04-21 2005-05-03 Medtronic, Inc. Atrial tracking recovery to restore cardiac resynchronization therapy in dual chamber tracking modes
WO2005020784A2 (en) 2003-05-23 2005-03-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
WO2004111654A2 (en) 2003-06-06 2004-12-23 Ciphergen Biosystems, Inc. Serum biomarkers in ischaemic heart disease
US20050106100A1 (en) 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
EP1560025A3 (en) * 2003-10-03 2011-09-07 F. Hoffmann-La Roche AG Specific markers for diabetes
EP1522857A1 (en) * 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
DE10347436B4 (de) 2003-10-13 2007-08-02 Johann Wolfgang Goethe-Universität Frankfurt am Main In vitro Verfahren zur Diagnose der kardiovaskulären Funktionalität von Blut-abgeleiteter zirkulierender Vorläuferzellen (BDP)
US20060019890A1 (en) 2004-01-15 2006-01-26 Kapoun Ann M Method for treating cardiac remodeling following myocardial injury
WO2006026074A2 (en) 2004-08-04 2006-03-09 Duke University Atherosclerotic phenotype determinative genes and methods for using the same
CA2596469A1 (en) 2005-02-01 2006-08-10 Government Of The U.S.A, As Represented By The Secretary Department Of H Ealth & Human Services Biomarkers for tissue status
US20070092886A1 (en) 2005-03-22 2007-04-26 Raymond Tabibiazar Methods and compositions for diagnosis, monitoring and development of therapeutics for treatment of atherosclerotic disease
US7632634B2 (en) 2005-04-15 2009-12-15 University Of Maryland Biotechnology Institute Method and assay for early diagnosis of prostate cancer
US9592970B2 (en) 2008-07-17 2017-03-14 Toby D. Henderson Robotic gantry with end effector for product lifting
CA2742265C (en) 2008-10-29 2014-07-15 Bg Medicine, Inc. Galectin-3 immunoassay
KR20120104167A (ko) 2009-08-25 2012-09-20 비쥐 메디신, 인코포레이티드 갈렉틴―3 및 심장 재동기화 요법

Also Published As

Publication number Publication date
SI2317324T1 (sl) 2015-11-30
CN1879022B (zh) 2012-10-17
US20110104722A1 (en) 2011-05-05
CN102998458A (zh) 2013-03-27
CA2542033A1 (en) 2005-05-06
PL2317324T3 (pl) 2015-10-30
CY1116147T1 (el) 2017-02-08
US20080193954A1 (en) 2008-08-14
EP2317324B1 (en) 2014-11-12
ES2530567T3 (es) 2015-03-03
JP2015171365A (ja) 2015-10-01
JP5580774B2 (ja) 2014-08-27
AU2009227844A1 (en) 2009-11-26
US20150037353A1 (en) 2015-02-05
US8084276B2 (en) 2011-12-27
CY1112359T1 (el) 2015-12-09
PT1682907E (pt) 2012-02-03
JP2011177184A (ja) 2011-09-15
EP2317324A1 (en) 2011-05-04
AU2004284496B2 (en) 2009-08-06
CA2842308A1 (en) 2005-05-06
PT2317324E (pt) 2015-02-17
SI1682907T1 (sl) 2012-03-30
AU2009227844B2 (en) 2012-07-19
EP1682907B1 (en) 2011-11-02
WO2005040817A1 (en) 2005-05-06
ATE532073T1 (de) 2011-11-15
DK1682907T3 (da) 2012-08-13
JP5789009B2 (ja) 2015-10-07
HK1101426A1 (en) 2007-10-18
JP4840744B2 (ja) 2011-12-21
CN1879022A (zh) 2006-12-13
CN102998458B (zh) 2015-07-22
JP2007508527A (ja) 2007-04-05
AU2004284496A1 (en) 2005-05-06
EP1682907A1 (en) 2006-07-26
CA2542033C (en) 2014-04-29
HK1184534A1 (zh) 2014-01-24
JP2014115297A (ja) 2014-06-26
US20130189716A1 (en) 2013-07-25
JP2010279378A (ja) 2010-12-16
EP1522857A1 (en) 2005-04-13
DK2317324T3 (en) 2015-02-16
PL1682907T3 (pl) 2012-03-30
US7888137B2 (en) 2011-02-15
AU2004284496C1 (en) 2010-03-04
US20120220532A1 (en) 2012-08-30
EP2919012A1 (en) 2015-09-16

Similar Documents

Publication Publication Date Title
ES2377012T3 (es) Método para identificar un sujeto susceptible de desarrollar insuficiencia cardíaca determinando el nivel de galectina-3 o trombospondina-2
SK2162001A3 (en) Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs
JP2025520135A (ja) Ｃｆ４８腎臓損傷バイオマーカー及び腎臓損傷治療薬における用途
US8153376B2 (en) Means and methods for diagnosing and/or treating a subject at risk of developing heart failure
CN115786513B (zh) Itga8在拉帕替尼耐药的her2阳性胃癌诊断、治疗中的应用
AU2012244071B2 (en) Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
Gao et al. Presenilin2 D439A mutation induces dysfunction of mitochondrial Fusion/Fission dynamics and abnormal regulation of GTPase activity
CN119700741A (zh) 大蒜素在预防和治疗川崎病药物中的应用
Morellato KIAA1217 is a novel protein in the synapse that interacts with PSD-95 and Shank3 andcontrols dendritic spines’ number and morphology
HK1184534B (en) Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
HK1101426B (en) Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
Kaye et al. UltraRapid Communication
Magharious Targeting the Phosphatidylinositide-3 Kinase Pathway and the Mitogen-Activated-Protein Kinase Pathway through Thymosin-β4, Exercise, and Negative Regulators to Promote Retinal Ganglion Cell Survival or Regeneration